COMMUNIQUÉS West-GlobeNewswire

Assemblée Générale Mixte du 3 juin 2026
13/05/2026
Châtillon, France, le 13 mai 2026 Assemblée Générale Mixte du 3 juin 2026 Modalités de mise à disposition des informations et documents préparatoires à l’Assemblée Générale Mixte DBV Technologies (Euronext : DBV – ISIN [...]
EDAP | Focal One to Host Investor Day on June 1, 2026
13/05/2026
AUSTIN, Texas, May 13, 2026 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), the global leader in robotic energy-based therapies, today announced that it will host an Investor Day for analysts and investors at 8:00 am ET [...]
Rapid Micro Biosystems Reports First Quarter 2026 Financial Results
13/05/2026
Reports first quarter 2026 total revenue of $8.0 million , representing 11% growth compared to the first quarter of 2025 Placed 6 Growth Direct systems in the first quarter 2026 compared to 3 systems in the first [...]
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
13/05/2026
First clinical data from PRMT5/RAS(ON) combination trial to be pre sented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points BOSTON, May 13, [...]
SeaStar Medical Reports First Quarter Financial Results and Provides Business Updates
13/05/2026
Added 7 top-rated children’s hospitals to QUELIMMUNE ® pediatric acute kidney injury (AKI) customer base, increasing first quarter revenue 69% versus first quarter 2025 revenue Advanced enrollment in the NEUTRALIZE-AKI [...]
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
13/05/2026
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as [...]
Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update
13/05/2026
Initiation of SLIM-1™ clinical trial, a Phase 1 study of NPM-139, a semaglutide implant under development for chronic weight management, on track for mid-year 2026 $28 million in cash, cash equivalents, restricted cash [...]
Dyadic Announces First Quarter 2026 Financial Results and Highlights Recent Company Progress
13/05/2026
Received initial purchase orders for recombinant bovine transferrin from customers in the cultivated meat industry Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using [...]
Bionano Reports First Quarter 2026 Results and Provides a Business Update
13/05/2026
Conference call today, May 13, 2026, at 4:30 PM ET SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2026. "The [...]
Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
13/05/2026
Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026 Affirms existing clinical data is sufficient for submitting regulatory applications in Canada, European Union, and the United [...]
Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights
13/05/2026
Phase 1 proof-of-mechanism study of EQ504 on track to initiate in mid-2026, with data expected approximately six months thereafter Equillium appoints Snehal Naik, Ph.D., as Chief Development Officer to lead clinical [...]
Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
13/05/2026
Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi ® revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position increased to $27 [...]
aTyr Pharma to Participate in Upcoming Investor Conferences
13/05/2026
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA [...]
MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation
13/05/2026
Manufacturing operations divestiture sharpens focus on core capabilities in novel drug discovery and development Manufacturing divestiture and expanded monetization of ZYNYZ royalty anticipated to provide up to $202.5 [...]
Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results
13/05/2026
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc. (NASDAQ: BLTE), (“Belite Bio®” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics [...]
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
13/05/2026
COPENHAGEN, Denmark, May 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company’s shares/related securities by persons holding managerial [...]
Mdxhealth Reports Q1-2026 Results
13/05/2026
Mdxhealth Reports Q1-2026 Results Conference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, California – May 13, 2026 ( GlobeNewswire ) – Mdxhealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading [...]
IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization
13/05/2026
Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagement Northeast kidney transplant center (among the top 10 in the U.S.) is first to sign clinical [...]
Medicenna Announces the Launch of a Marketed Public Offering of Securities
13/05/2026
NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO and HOUSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a [...]

Pages